What is he best known for?
The fields of study he is best known for:
His primary areas of investigation include Cancer research, Multiple myeloma, Immunology, Bone marrow and Protein kinase B.
The Cancer research study combines topics in areas such as Imatinib mesylate, Transfection, GAB2, PI3K/AKT/mTOR pathway and Cytotoxicity.
His Multiple myeloma research integrates issues from Pharmacology and Proteasome.
His studies in Immunology integrate themes in fields like Natural killer cell, Peripheral blood mononuclear cell, Haematopoiesis and Osteoclast.
His research in Bone marrow intersects with topics in Cytokine, Stromal cell and Antibody-dependent cell-mediated cytotoxicity.
His work carried out in the field of Thalidomide brings together such families of science as Immune system and Cell killing.
His most cited work include:
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (827 citations)
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (827 citations)
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (827 citations)
What are the main themes of his work throughout his whole career to date?
Klaus Podar mainly focuses on Cancer research, Multiple myeloma, Bortezomib, Stromal cell and Cell growth.
His Cancer research research is multidisciplinary, incorporating elements of Immunology, Bone marrow and Apoptosis.
Klaus Podar has included themes like Peripheral blood mononuclear cell, Endocrinology, Cell killing and CD40 in his Bone marrow study.
Many of his research projects under Multiple myeloma are closely connected to Drug resistance with Drug resistance, tying the diverse disciplines of science together.
His Bortezomib study integrates concerns from other disciplines, such as Proteasome inhibitor, Proteasome and Downregulation and upregulation.
His Cell growth research incorporates themes from Cell and Protein kinase B, Signal transduction, Kinase, Cell biology.
He most often published in these fields:
- Cancer research (76.15%)
- Multiple myeloma (40.37%)
- Bortezomib (41.28%)
What were the highlights of his more recent work (between 2008-2019)?
- Cancer research (76.15%)
- Multiple myeloma (40.37%)
- Bortezomib (41.28%)
In recent papers he was focusing on the following fields of study:
Klaus Podar spends much of his time researching Cancer research, Multiple myeloma, Bortezomib, Bone marrow and Cell growth.
Klaus Podar has researched Cancer research in several fields, including Apoptosis, Signal transduction and Cell adhesion.
In the field of Multiple myeloma, his study on Lenalidomide overlaps with subjects such as Drug resistance.
His Bortezomib research is within the category of Immunology.
His Bone marrow study incorporates themes from Pharmacology and MAPK/ERK pathway.
The concepts of his Cell growth study are interwoven with issues in Kinase, Cell biology and Janus kinase inhibitor.
Between 2008 and 2019, his most popular works were:
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells (277 citations)
- Bone marrow microenvironment and the identification of new targets for myeloma therapy. (264 citations)
- Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target (183 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
